Document registry

• Assessment cycle 2026 Q3

  CEI-AC-15Assessment-cycle record2026-q3

  Record of documents ratified in the 2026 Q3 assessment cycle.

  18 Sep 2026
• Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier disorders: tolerability and discontinuation

  CEI-ES-096Evidence synthesis2026-q3

  In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…

  Moderate07 Sep 2026
• Synthesis: Survodutide in obesity and overweight in adults: effect on the anchor outcome

  CEI-ES-047Evidence synthesis2026-q3

  In the population defined for obesity and overweight in adults, what is the effect of Survodutide compared with the comparator used in its contributing trials on the…

  Moderate05 Sep 2026
• Synthesis: Counter-ion content and its effect on delivered peptide mass

  CEI-ES-013Evidence synthesis2026-q3

  How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?

  High01 Sep 2026
• Synthesis: Analytical surveys of unregulated peptide supply

  CEI-ES-015Evidence synthesis2026-q3

  What do published analytical surveys report about the identity, purity and content of peptides obtained from unregulated suppliers?

  Low31 Aug 2026
• Synthesis: Gonadorelin in growth hormone deficiency and growth-hormone secretagogue pharmacology: effect on the anchor outcome

  CEI-ES-061Evidence synthesis2026-q3

  In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Gonadorelin compared with the comparator used…

  Moderate29 Aug 2026
• Supplier dossier: Qingdao Saber Technology Pharmaceutical

  CEI-SD-19Supplier dossier2026-q3

  Peptides, SARMs, injectable oils and raw materials.

  29 Aug 2026
• Synthesis: Thymosin alpha-1 in immune modulation and adjunctive immunotherapy: durability of effect

  CEI-ES-130Evidence synthesis2026-q3

  In the population defined for immune modulation and adjunctive immunotherapy, is the effect of Thymosin alpha-1 maintained across the full duration of the contributing…

  Moderate26 Aug 2026
• Standard CEI-MS-11

  CEI-MS-11Methodological standard2026-q3

  Determination of aggregate content by size-exclusion chromatography

  High26 Aug 2026
• Monograph: NAD+ (nicotinamide adenine dinucleotide)

  CEI-MN-045Compound monograph2026-q3

  Endogenous pyridine dinucleotide coenzyme. NAD+ is the central redox coenzyme of intermediary metabolism and the substrate of the sirtuin and poly-ADP-ribose polymerase enzyme families. Tissue…

  Very low23 Aug 2026
• Synthesis: Liraglutide in obesity and overweight in adults: effect on the anchor outcome

  CEI-ES-050Evidence synthesis2026-q3

  In the population defined for obesity and overweight in adults, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the…

  High20 Aug 2026
• Synthesis: Dual and triple incretin receptor agonists compared with single glucagon-like peptide-1 receptor agonists for weight reduction

  CEI-ES-002Evidence synthesis2026-q3

  In adults with obesity, does a multi-receptor incretin agonist produce a larger reduction in body weight than a single glucagon-like peptide-1 receptor agonist?

  Moderate19 Aug 2026
• Draft synthesis: Bacterial endotoxin in research-supply peptide presentations

  CEI-CP-116Public comment period2026-q3

  Consultation on the draft of this analytical evidence review, which registers the question: What is known about bacterial endotoxin content in peptides supplied for…

  10 Aug 2026
• Synthesis: Amylin analogues as monotherapy and in combination

  CEI-ES-022Evidence synthesis2026-q3

  What is the effect of an amylin receptor agonist alone and in combination with a glucagon-like peptide-1 receptor agonist on body weight?

  Moderate10 Aug 2026
• Draft monograph: Exenatide

  CEI-CP-049Public comment period2026-q3

  Consultation on the draft monograph for Exenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's…

  07 Aug 2026
• Indication assessment: Peripheral arterial disease with intermittent claudication

  CEI-IN-16Indication assessment2026-q3

  Atherosclerotic obstruction of the lower-limb arteries producing exertional ischaemic symptoms, with objective confirmation by ankle–brachial index or imaging.

  06 Aug 2026
• Draft monograph: amycretin

  CEI-CP-039Public comment period2026-q3

  Consultation on the draft monograph for amycretin, a co-agonist at the glucagon-like peptide-1 and amylin receptors. The draft grades the principal assessed outcome at…

  05 Aug 2026
• Draft methodology document, version 4

  CEI-CP-032Public comment period2026-q3

  Consultation on the fourth version of the Institute's methodology document, which describes how a question is registered, how evidence is searched and screened, how…

  31 Jul 2026
• Bibliographic record: PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide…

  CEI-BR-001Bibliographic record2026-q3

  Diabetes Care 2019

  30 Jul 2026
• Bibliographic record: Continued treatment with tirzepatide for maintenance of weight reduction in adults with…

  CEI-BR-002Bibliographic record2026-q3

  JAMA 2024

  30 Jul 2026
• Bibliographic record: Tirzepatide as compared with semaglutide for the treatment of obesity

  CEI-BR-003Bibliographic record2026-q3

  New England Journal of Medicine 2025

  30 Jul 2026
• Bibliographic record: GRADE guidelines: 3. Rating the quality of evidence

  CEI-BR-004Bibliographic record2026-q3

  Journal of Clinical Epidemiology 2011

  30 Jul 2026
• Bibliographic record: GLP-1 receptor agonists and the risk of thyroid cancer

  CEI-BR-005Bibliographic record2026-q3

  Diabetes Care 2023

  30 Jul 2026
• Bibliographic record: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week…

  CEI-BR-006Bibliographic record2026-q3

  The Lancet 2009

  30 Jul 2026
• Bibliographic record: Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and…

  CEI-BR-007Bibliographic record2026-q3

  American Journal of Gastroenterology 2024

  30 Jul 2026
• Bibliographic record: Rational design of stable lyophilized protein formulations: some practical advice

  CEI-BR-008Bibliographic record2026-q3

  Pharmaceutical Research 1997

  30 Jul 2026
• Bibliographic record: Analytical and forensic aspects of counterfeit peptide hormones

  CEI-BR-009Bibliographic record2026-q3

  Drug Testing and Analysis 2023

  30 Jul 2026
• Bibliographic record: Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized…

  CEI-BR-010Bibliographic record2026-q3

  Women’s Health 2016

  30 Jul 2026
• Bibliographic record: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2…

  CEI-BR-011Bibliographic record2026-q3

  Molecular Metabolism 2018

  30 Jul 2026
• Bibliographic record: Related impurities in peptide medicines

  CEI-BR-012Bibliographic record2026-q3

  Journal of Pharmaceutical and Biomedical Analysis 2014

  30 Jul 2026
• Bibliographic record: Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on…

  CEI-BR-013Bibliographic record2026-q3

  JAMA 2022

  30 Jul 2026
• Bibliographic record: Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes…

  CEI-BR-014Bibliographic record2026-q3

  The Lancet 2021

  30 Jul 2026
• Bibliographic record: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk…

  CEI-BR-015Bibliographic record2026-q3

  The Lancet 2021

  30 Jul 2026
• Bibliographic record: Mechanisms of action and therapeutic application of glucagon-like peptide-1

  CEI-BR-016Bibliographic record2026-q3

  Cell Metabolism 2018

  30 Jul 2026
• Bibliographic record: Bias in meta-analysis detected by a simple, graphical test

  CEI-BR-017Bibliographic record2026-q3

  BMJ 1997

  30 Jul 2026
• Bibliographic record: Mounjaro (tirzepatide) — Summary of Product Characteristics

  CEI-BR-018Bibliographic record2026-q3

  EMA European Public Assessment Report 2024

  30 Jul 2026
• Bibliographic record: Wegovy (semaglutide) — Summary of Product Characteristics

  CEI-BR-019Bibliographic record2026-q3

  EMA European Public Assessment Report 2024

  30 Jul 2026
• Bibliographic record: Metabolic effects of a growth hormone-releasing factor in patients with HIV

  CEI-BR-020Bibliographic record2026-q3

  New England Journal of Medicine 2007

  30 Jul 2026
• Bibliographic record: FDA’s concerns with unapproved GLP-1 drugs used for weight loss

  CEI-BR-021Bibliographic record2026-q3

  FDA Drug Safety Communication 2024

  30 Jul 2026
• Bibliographic record: MOUNJARO (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing…

  CEI-BR-022Bibliographic record2026-q3

  FDA Approved Labeling 2024

  30 Jul 2026

page 1 of 41